Fast Five Quiz: Management of Mantle Cell Lymphoma

Elwyn C. Cabebe, MD


November 17, 2021

Increased proliferation rate, as measured by Ki67 immunostaining, is regarded as a high-risk prognostic factor in both the frontline and relapsed settings.

A strong association between TP53 mutations and inferior outcomes following treatment with either intensive chemo-immunotherapy or Bruton tyrosine kinase inhibitors has been demonstrated. TP53 mutations are frequently associated with a high proliferation rate.

Although MCL does not carry a favorable prognosis overall, patients with transformed MCL (ie, patients with prior classic histology whose histologic variant evolves to blastoid and pleomorphic histologic at relapse) are at the highest risk for poor outcomes. Other negative prognostic features include various high-risk genetic features such as mutations within NOTCH1, NOTCH2, and KMT2D and mutations or copy number loss of CDKN2A.

Learn more about the management of patients newly diagnosed with MCL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.